SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-005811
Filing Date
2023-01-30
Accepted
2023-01-30 08:05:22
Documents
13
Period of Report
2023-01-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea172250-8k_protara.htm   iXBRL 8-K 35444
2 PRESS RELEASE DATED JANUARY 30, 2023, ISSUED BY THE REGISTRANT ea172250ex99-1_protara.htm EX-99.1 11188
  Complete submission text file 0001213900-23-005811.txt   227716

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tara-20230130.xsd EX-101.SCH 3230
4 XBRL LABEL FILE tara-20230130_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tara-20230130_pre.xml EX-101.PRE 22361
7 EXTRACTED XBRL INSTANCE DOCUMENT ea172250-8k_protara_htm.xml XML 3611
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36694 | Film No.: 23565303
SIC: 2836 Biological Products, (No Diagnostic Substances)